Recent investigations and arrests targeting telehealth companies, providing virtual treatment for Attention Deficit Hyperactivity Disorder (ADHD) appear to be part of increased scrutiny in the telehealth sector providing prescriptions for controlled substances. These...
Introduction As cryptocurrencies continue to integrate into mainstream finance, the ecosystem has seen a rise in sophisticated scams, prompting significant legal and regulatory challenges. To address this, major cryptocurrency exchanges and tech companies like...
On May 13, 2024, the U.S. Department of Justice (DOJ) issued a press release touting its 2023 False Claims Act (FCA) “accomplishments” – amassing nearly $2.7 billion in settlements and judgments. This figure, while noteworthy, is part of a broader narrative of...
On May 16, 2024, the US Department of Justice (DOJ) officially took steps to reclassify marijuana as a Schedule III controlled substance. This decision marks a significant shift in US policy on cannabis and has the potential to open new possibilities for the future of...
On April 4, 2024, an indictment was filed in the Tampa Division of the Middle District of Florida (Case 8:24-cr-00156-TPB-NHA) which illustrates the risk to medical providers and sellers of medical equipment of relying on marketing companies for leads. This practice...
